4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Average Recommendation of “Moderate Buy” from Analysts

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) has been given a consensus recommendation of “Moderate Buy” by the ten ratings firms that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, seven have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $29.6250.

A number of equities analysts recently issued reports on FDMT shares. HC Wainwright reiterated a “buy” rating and issued a $36.00 target price on shares of 4D Molecular Therapeutics in a research report on Monday, July 20th. Chardan Capital upgraded shares of 4D Molecular Therapeutics to a “strong-buy” rating in a research report on Tuesday, July 28th. Wall Street Zen lowered shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Friday, July 17th. Finally, B. Riley Financial reiterated a “buy” rating on shares of 4D Molecular Therapeutics in a research note on Monday, August 17th.

Insiders Place Their Bets

In other news, insider David Kirn sold 114,746 shares of the business’s stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $10.47, for a total value of $1,201,390.62. Following the sale, the insider owned 942,485 shares of the company’s stock, valued at approximately $9,867,817.95. The trade was a 10.85% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Scott Bizily sold 9,810 shares of the company’s stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $12.00, for a total value of $117,720.00. Following the completion of the sale, the insider owned 8,617 shares of the company’s stock, valued at approximately $103,404. This trade represents a 53.24% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 200,496 shares of company stock valued at $2,240,244. 7.90% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Legal & General Group Plc acquired a new stake in 4D Molecular Therapeutics in the 2nd quarter valued at about $59,000. Wexford Capital LP acquired a new position in shares of 4D Molecular Therapeutics in the 3rd quarter worth approximately $41,000. Daiwa Securities Group Inc. grew its stake in shares of 4D Molecular Therapeutics by 3,362.0% in the 4th quarter. Daiwa Securities Group Inc. now owns 6,370 shares of the company’s stock worth $48,000 after purchasing an additional 6,186 shares during the last quarter. Susquehanna Portfolio Strategies LLC bought a new stake in shares of 4D Molecular Therapeutics in the 4th quarter worth approximately $77,000. Finally, Susquehanna Fundamental Investments LLC bought a new stake in shares of 4D Molecular Therapeutics in the 2nd quarter worth approximately $148,000. 99.27% of the stock is currently owned by institutional investors.

4D Molecular Therapeutics Stock Performance

NASDAQ:FDMT opened at $15.83 on Monday. 4D Molecular Therapeutics has a 1 year low of $5.97 and a 1 year high of $16.93. The stock has a market cap of $874.45 million, a price-to-earnings ratio of -6.02 and a beta of 2.73. The business has a fifty day moving average of $11.61 and a 200-day moving average of $10.12. The company has a debt-to-equity ratio of 0.05, a quick ratio of 8.03 and a current ratio of 8.03.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($1.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.02). The company had revenue of $3.78 million for the quarter, compared to the consensus estimate of $3.62 million. 4D Molecular Therapeutics had a negative net margin of 194.74% and a negative return on equity of 41.33%. Equities analysts predict that 4D Molecular Therapeutics will post -4.09 earnings per share for the current year.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.